GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » Quick Ratio

Nascent Biotech (Nascent Biotech) Quick Ratio : 1.05 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Nascent Biotech's quick ratio for the quarter that ended in Dec. 2023 was 1.05.

Nascent Biotech has a quick ratio of 1.05. It generally indicates good short-term financial strength.

The historical rank and industry rank for Nascent Biotech's Quick Ratio or its related term are showing as below:

NBIO' s Quick Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.21   Max: 1.71
Current: 1.05

During the past 7 years, Nascent Biotech's highest Quick Ratio was 1.71. The lowest was 0.01. And the median was 0.21.

NBIO's Quick Ratio is ranked worse than
79.69% of 1546 companies
in the Biotechnology industry
Industry Median: 3.595 vs NBIO: 1.05

Nascent Biotech Quick Ratio Historical Data

The historical data trend for Nascent Biotech's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech Quick Ratio Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Quick Ratio
Get a 7-Day Free Trial 0.21 - 0.61 0.14 0.16

Nascent Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.16 0.06 0.99 1.05

Competitive Comparison of Nascent Biotech's Quick Ratio

For the Biotechnology subindustry, Nascent Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Biotech's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's Quick Ratio falls into.



Nascent Biotech Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Nascent Biotech's Quick Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Quick Ratio (A: Mar. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.255-0)/1.551
=0.16

Nascent Biotech's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.641-0)/0.611
=1.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nascent Biotech  (OTCPK:NBIO) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Nascent Biotech Quick Ratio Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nascent Biotech (Nascent Biotech) Business Description

Traded in Other Exchanges
N/A
Address
631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Executives
Lowell Thomas Holden director, officer: CFO 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick director, officer: President 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price director, officer: Senior VP Business Development 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas director 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy director, officer: CEO 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121